Blue Sail Medical Enters Structural Heart Disease Market with First Successful Implantation of Allegra™ TAVI System
Recently, VCBeat (WeChat Official Account: vcbeat) learned that the first Allegra™ TAVI (Transcatheter Aortic Valve Implantation) system was successfully implanted in an 87-year-old patient at Swansea Morriston Hospital in the UK. Kenneth Graham, Vice President of Blue Sail Medical and Head of Biosensors International (Europe), announced that this patient became the first in the UK to receive the Allegra™ TAVI system. The success of this procedure marks Blue Sail Medical’s formal entry into the field of structural heart disease.
As of the conclusion of the surgery, the patient’s condition is stable, and the procedural outcome is excellent. This operation is expected to significantly improve her future quality of life. The patient’s preoperative cardiac valve pressure gradient was greater than 70 mmHg, whereas the postoperative pressure gradient dropped to less than 3 mmHg. Despite the complexity of the case, the patient experienced no arrhythmias or vascular or cerebral complications during the procedure, which lasted less than two hours in total.
Dr. Smith, the lead surgeon, was highly satisfied with the outcomes of this procedure. The patient suffered from severe aortic stenosis, a condition associated with a poor prognosis. In elderly patients, the hemodynamic alterations caused by aortic stenosis pose significant risks; implantation of the Allegra™ TAVI system can mitigate these hemodynamic changes. During the procedure, Dr. Smith was deeply impressed by the technology, ease of use, and safety benefits for the patient offered by the Allegra™ system.
The Allegra™ valve features a laser-cut, self-expanding nitinol alloy stent structure with a manually implanted bovine pericardial bioprosthetic valve. The long-term efficacy of bovine pericardium has been demonstrated in surgical practice. The Allegra™ valve is equipped with six radiopaque gold markers to provide excellent visibility during implantation.
Allegra™ Valve
Following the success of the first procedure, the Allegra™ TAVI system will be implanted in more patients worldwide, significantly improving their quality of life and benefiting a greater number of patients.
On July 1, 2018, Biosensors International, the cardiovascular and cerebrovascular business platform under Blue Sail Medical, reached a distribution agreement for the Allegra™ TAVI system, which is developed and manufactured using new valve technology by NVT (Muri, Switzerland). Li Bingrong, President of Blue Sail Medical, emphasized that this marks a milestone in the partnership and collaboration between Blue Sail Medical and NVT. The company looks forward to continuing joint efforts to successfully enter the TAVI markets in the United Kingdom and Ireland while expanding into other markets, thereby introducing the most advanced international medical devices and therapeutic approaches to China.
Li Bingrong stated, “The success of this surgery marks Blue Sail Medical’s official entry into the field of structural heart disease. In the future, we will continue to enrich our product portfolio and strive to become a comprehensive solutions provider in the global cardiovascular sector!”
In November 2016, the “Guidelines for the Development Plan of the Pharmaceutical Industry During the 13th Five-Year Plan Period,” jointly formulated by six national ministries and commissions, listed implantable and interventional products and medical materials as one of the six key areas for priority development. The Plan explicitly called for accelerating the application of new material technologies and, in response to clinical treatment needs in cardiology and other specialties, continuing to speed up the innovation and industrialization of new medical device products such as bioresorbable vascular scaffolds, prosthetic heart valves, and other devices in the field of interventional therapy. With population aging, a rapidly growing prevalence of cardiovascular diseases, and increasing public awareness of health management, interventional devices for structural heart disease will usher in significant growth opportunities, boasting substantial market capacity and promising prospects. Blue Sail Medical will continue to deepen its engagement in the cerebrovascular and cardiovascular fields, dedicating itself to the research and development, production, and sales of cardiology-related medical devices. Its entry into the field of interventional devices for structural heart disease will undoubtedly create new growth drivers for the company’s long-term development.
Blue Sail Medical is a leading medical device company with a comprehensive portfolio spanning both low-to-mid-value and high-value consumables. The low-to-mid-value consumables segment primarily offers medical protection products, including medical gloves, health protective gloves, first-aid kits, and medical dressings, with its flagship PVC gloves holding a 22% global market share. The high-value consumables segment focuses on coronary stents and related interventional cardiac surgical devices, operated through its Singapore-based subsidiary, Biosensors International. This business operates in over 90 countries worldwide and ranks fourth globally in the coronary stent market.